| Original language | English (US) |
|---|---|
| Pages (from-to) | 626-627 |
| Number of pages | 2 |
| Journal | Nature Reviews Gastroenterology and Hepatology |
| Volume | 20 |
| Issue number | 10 |
| DOIs |
|
| State | Published - Oct 2023 |
ASJC Scopus subject areas
- Hepatology
- Gastroenterology
Access to Document
Other files and links
Cite this
- APA
- Standard
- Harvard
- Vancouver
- Author
- BIBTEX
- RIS
In: Nature Reviews Gastroenterology and Hepatology, Vol. 20, No. 10, 10.2023, p. 626-627.
Research output: Contribution to journal › Comment/debate › peer-review
}
TY - JOUR
T1 - Measuring NAFLD models of care
AU - Allen, Alina M.
AU - Younossi, Zobair M.
AU - Tsochatzis, Emmanuel A.
AU - Alazawi, William
AU - Zelber-Sagi, Shira
AU - Arab, Juan Pablo
AU - Cusi, Kenneth
AU - Lazarus, Jeffrey V.
N1 - Funding Information: A.M.A. has received grant support to her institution from the National Institutes of Health (NIH) (DK128127), Novo Nordisk, Pfizer and Target Pharma and has participated in advisory boards for Novo Nordisk, outside of the submitted work. Z.M.Y. has received consulting fees from Gilead, Intercept, Siemens, Novo Nordisk, Madrigal, Merck, Quest and Bristol Myers Squibb, outside of the submitted work. E.A.T. has participated in advisory boards for and received consulting fees from Boehringer, Pfizer and Novo Nordisk and has given lectures for Novo Nordisk and Dr Falk, outside of the submitted work. S.Z-S. has given presentations for and received meeting and/or travel support from AbbVie, outside of the submitted work. K.C. has received grant support to his institution from Echosens, Inventiva, Poxel, Novo, Labcorp and Zydus, consulting fees from BMS, Lilly, Madrigal, Merck, Myovant, Novo Nordisk, Prosciento, Quest, Sagimet, Sonic Incytes and Terns and other support from Echosens, Inventiva, Poxel, Labcorp and Zydus, outside of the submitted work. J.V.L. acknowledges grants and speaker fees from AbbVie, Gilead Sciences, MSD and Roche Diagnostics to his institution, speaker fees from Intercept, Janssen, Novo Nordisk and ViiV and consulting fees from Novavax, outside of the submitted work. J.V.L. also acknowledges support to ISGlobal from the grant CEX2018-000806-S funded by MCIN/AEI/10.13039/501100011033 and the “Generalitat de Catalunya” through the CERCA programme, outside of the submitted work. W.A. and J.P.A. declare no competing interests.
PY - 2023/10
Y1 - 2023/10
UR - http://www.scopus.com/inward/record.url?scp=85161422674&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85161422674&partnerID=8YFLogxK
U2 - 10.1038/s41575-023-00798-9
DO - 10.1038/s41575-023-00798-9
M3 - Comment/debate
C2 - 37291278
AN - SCOPUS:85161422674
SN - 1759-5045
VL - 20
SP - 626
EP - 627
JO - Nature Reviews Gastroenterology and Hepatology
JF - Nature Reviews Gastroenterology and Hepatology
IS - 10
ER -